AngioDynamics, Inc. (ANGO) vs Prime Medicine, Inc. (PRME)
A side-by-side comparison of AngioDynamics, Inc. and Prime Medicine, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ANGO
AngioDynamics, Inc.
$14.42HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
PRME
Prime Medicine, Inc.
$3.53HealthcareDelayed quote: Oct 6, 2026, 3:55 PM EDT
Total return — ANGO vs PRME
growth of $100 · dividends reinvested · last 4yANGO +14.5% (+3.4%/yr)PRME -79.1% (-32.4%/yr)ANGO compounded faster over this window
Log scale — wide-divergence pair
ANGO PRME
ANGO vs PRME: by the numbers
- •PRME is the larger company ($637M vs $596M market cap).
- •Both run net losses; ANGO's is the smaller (-11.48% vs -4613.11% net margin).
- •ANGO grew revenue faster over the past five years (1.93% vs -2.32% CAGR).
Metrics side by side
Valuation
| Metric | ANGO | PRME |
|---|---|---|
| P/S ratio | 1.86 | 156.32 |
| P/B ratio | 3.49 | 15.99 |
| FCF yield | 0.09% | N/A |
Profitability
| Metric | ANGO | PRME |
|---|---|---|
| Gross margin | 54.62% | -58.05% |
| Operating margin | -12.47% | -4498.06% |
| Net margin | -11.48% | -4613.11% |
| ROE | -21.51% | -471.98% |
| ROIC | -20.75% | -90.42% |
Growth (annualized)
| Metric | ANGO | PRME |
|---|---|---|
| Revenue CAGR (5Y) | 1.93% | -2.32% |
| FCF CAGR (5Y) | -51.49% | N/A |
| Total return CAGR (5Y) | -10.80% | N/A |
Frequently asked
- Which has grown faster, ANGO or PRME?
- Over the past five years, ANGO grew revenue faster — ANGO at a 1.93% CAGR versus PRME at -2.32%.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.